European Lung Cancer Working Party Clinical Practice Guidelines. Non-Small Cell Lung Cancer: III. Metastatic disease

The present guidelines on the management of advanced non-small cell lung cancer (NS CLC) were formulated by the ELCWP in October 2006. They are designed to answer the following twelve questions: 1) What benefits can be expected from chemotherapy and what are the treatment objectives? 2) What are the active chemotherapeutic drugs for which efficacy has been shown? 3) Which are the most effective platinum-based regimens? 4) Which is the indicated dosage of cisplatin? 5) Can carboplatin be substituted for cisplatin? 6) Which is the optimal number of cycles to be administered? 7) Can non-platinum based regimens be substituted for platinum based chemotherapy as first-line treatment? 8) Is there an indication for sequential chemotherapy? 9) What is the efficacy of salvage chemotherapy and which drugs should be used in that indication? 10) What is the place of targeted therapies? 11) What is the place of chemotherapy in the management of a patient with brain metastases? 12) Which specific drugs can be used for the patient with bone metastases

Effect of almitrine on the mechanics of breathing in normal man

The acute effect of almitrine on lung volumes, maximal expiratory flow, lung elasticity, airway resistance, single and multiple breath nitrogen washoutes were evaluated in eight young nonsmoking male subjects during a double-blind placebo controlled cross-over trial. None of these indices varied after oral administration of 1.5 mg/kg body weight of almitrine.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Inspired volume dependence of the slope of the alveolar plateau

Two series of experiments were performed in nine healthy subjects. In series I, 96 single breath tests were performed in two subjects. The inspired gas contained 90% O2, 5% He and 5% SF6 and the slope of the alveolar plateau for N2, He and SF6 was computed. The following experimental conditions were considered variable: inspired volume with preinspiratory lung volume equal to residual volume or functional residual capacity (FRC), both with and without 10 sec breath-holding. In series II, each of the other 7 subjects performed 12 single breath N2 tests in which the subject inspired both 1 L and an inspiratory capacity (IC) of O2 from FRC with and without 10 sec breath holding. The main experimental observation is that without breath-holding the absolute value of the slope of the alveolar plateau is larger for 1 L inspiration than for an IC inspiration, whereas this volume dependence was small after 10 sec of breath-holding. Based on Milic-Emili model of the lung and on simulations of a multibranch point model of the acinus we conclude that, in so far as these models adequately describe gas distribution in the lung, intraregional parallel units presenting a sequential convective flow play an important role in the genesis of the alveolar plateau.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Preinspiratory lung volume dependence of the slope of the alveolar plateau

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer

SCOPUS: le.jinfo:eu-repo/semantics/publishe

A phase II study evaluating CA Vi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer

Two consecutive trials were conducted, testing the CAVi (cyclophosphamide 1 g/m2; doxorubicin (adriamycin) 45 mg/m2; vincristine 1.4 mg/m2; all i.v. on day 1; every 3 weeks) combination as salvage therapy for small cell lung cancer (SCLC) after first line treatment with etoposide plus vindesine with or without cisplatin. In the first study, CAVi was used alone. In 45 evaluable patients, 6 objective responses were observed (13%; Confidence Limits C.L.): 5.1-20.8). In the second study, CAVi was potentiated with 2 mg/kg of ampholiposomes given i.v. 24 h prior to chemotherapy. Ampholiposomes consisted of amphotericin B entrapped into sonicated liposomes made of egg lecithin, cholesterol and stearylamine in the molar ratio 4:3:1 (lipid concentration: 20 mg/ml). Among 11 evaluable patients, 6 objective responses were observed (55%; Confidence Limits: 23.4-83.3) and toxicity was not increased. These preliminary results suggest that ampholiposomes might overcome resistance to chemotherapy in SCLC and should encourage controlled studies.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report

SCOPUS: cp.jinfo:eu-repo/semantics/publishe

A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe